^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    2d
    Baricitinib Curative Repression of HIV-1 (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Emory University | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    CD4 (CD4 Molecule)
    5d
    BRAVE-AA-PEDS: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (clinicaltrials.gov)
    P3, N=595, Recruiting, Eli Lilly and Company | Trial completion date: Aug 2029 --> Feb 2030 | Trial primary completion date: Sep 2027 --> Mar 2028
    Trial completion date • Trial primary completion date
    6d
    BAPT: Baricitinib for Post-HSCT Persistent Thrombocytopenia (clinicaltrials.gov)
    P1/2, N=28, Not yet recruiting, Peking University People's Hospital
    New P1/2 trial
    7d
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    7d
    A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis (clinicaltrials.gov)
    P3, N=135, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P3 trial
    |
    imatinib • tofacitinib
    7d
    JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Shixiu Wu
    New P2 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    7d
    A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1) (2024-518556-22-00)
    P2/3, N=46, Completed, Medical University Of Vienna | Active, not recruiting --> Completed
    Trial completion
    8d
    Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target Trial. (PubMed, Respirology)
    UPA was found to be non-inferior to TOFA in improving 6-month lung transplantation-free survival among patients with MDA5+DM-ILD, with comparable safety.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    tofacitinib
    9d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2030 --> Jun 2030 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    10d
    Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study. (PubMed, Rheumatol Ther)
    Tofacitinib provided early and sustained improvement of disease signs and symptoms in patients with RA in Canada. Safety was consistent with the RA clinical program and the established tofacitinib clinical profile. Results were consistent with the interim analysis.
    Journal
    |
    CRP (C-reactive protein)
    |
    tofacitinib
    10d
    Successful Treatment of Severe Refractory Chronic Actinic Dermatitis with Upadacitinib: A Case Series of Four Patients. (PubMed, Clin Exp Dermatol)
    We describe four men (aged 44-65 years) with long-standing, severe CAD unresponsive to multiple systemic treatments, including immunosuppressants, dupilumab, and tofacitinib. Treatment was well tolerated, with only mild acneiform eruption and transient hypertriglyceridaemia in one case. These findings suggest that selective JAK1 inhibition may represent a therapeutic option in severe, treatment-refractory CAD.
    Journal
    |
    JAK1 (Janus Kinase 1)
    |
    tofacitinib • Dupixent (dupilumab)
    14d
    A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=64, Recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    flonoltinib